The Impact of Failure and Success Experience on Drug Development

DC FieldValueLanguage
dc.contributor.authorGarzón‐Vico, Antonio-
dc.contributor.authorRosier, Jan A.-
dc.contributor.authorGibbons, Patrick T.-
dc.contributor.authorMcNamara, Peter-
dc.date.accessioned2020-04-07T12:14:19Z-
dc.date.available2020-04-07T12:14:19Z-
dc.date.copyright2019 Product Development & Management Associationen_US
dc.date.issued2020-01-
dc.identifier.citationJournal of Product Innovation Managementen_US
dc.identifier.issn0737-6782-
dc.identifier.urihttp://hdl.handle.net/10197/11340-
dc.description.abstractIt is unclear whether the common belief that experience benefits new product development is driven by decision‐makers allocating more attention to success experience or more attention to failure experience. This article differentiates between the two aforementioned types of experience in order to explore their separate effects on new product development. We find that only late‐stage failure experience improves new product development, that success experience is more beneficial than late‐stage failure experience and that, while others’ related failure experience increases the likelihood of failure, others’ related success experience decreases it. We conducted our research in the context of drug development in the biotech industry and obtained our data from Pharma Projects. We employ logistic regression analysis to model the likelihood that a drug development project results in failure.en_US
dc.description.sponsorshipUniversity College Dublin Foundationen_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.rightsThis is the peer reviewed version of the following article: Garzón‐Vico, A. , Rosier, J. , Gibbons, P. and McNamara, P. (2019), The Impact of Failure and Success Experience on Drug Development. the Journal of Product Innovation Management, which has been published in final form at http://onlinelibrary.wiley.com/doi/10.1111/srt.12339/full. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.en_US
dc.subjectOrphan drugen_US
dc.subjectRare diseasesen_US
dc.titleThe Impact of Failure and Success Experience on Drug Developmenten_US
dc.typeJournal Articleen_US
dc.internal.authorcontactotherantonio.garzon@ucd.ieen_US
dc.statusPeer revieweden_US
dc.identifier.volume37en_US
dc.identifier.issue1en_US
dc.identifier.startpage74en_US
dc.identifier.endpage96en_US
dc.identifier.doi10.1111/jpim.12514-
dc.neeo.contributorGarzón‐Vico|Antonio|aut|-
dc.neeo.contributorRosier|Jan A.|aut|-
dc.neeo.contributorGibbons|Patrick T.|aut|-
dc.neeo.contributorMcNamara|Peter|aut|-
dc.date.embargo2021-10-12en_US
dc.description.othersponsorshipPerigoen_US
dc.date.updated2019-10-29T08:45:36Z-
item.fulltextWith Fulltext-
item.grantfulltextembargo_20211012-
Appears in Collections:Business Research Collection
Biomolecular and Biomedical Science Research Collection
Files in This Item:
Access to this item has been restricted by the copyright holder until:2021-10-12
File Description SizeFormat 
Garz-n-Vico_et_al-2019-Journal_of_Product_Innovation_Management.pdf383.29 kBAdobe PDF    Request a copy
Show simple item record

Page view(s)

331
Last Week
7
Last month
18
checked on Oct 24, 2020

Download(s)

30
checked on Oct 24, 2020

Google ScholarTM

Check

Altmetric


This item is available under the Attribution-NonCommercial-NoDerivs 3.0 Ireland. No item may be reproduced for commercial purposes. For other possible restrictions on use please refer to the publisher's URL where this is made available, or to notes contained in the item itself. Other terms may apply.